HomeLXRX • NASDAQ
Lexicon Pharmaceuticals Inc
$2.19
Pre-market:
$2.19
(0.00%)0.00
Closed: Mar 28, 8:31:30 AM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$2.19
Year range
$0.92 - $3.79
Market cap
539.26M USD
Avg Volume
5.74M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
702.00K2,407.14%
Operating expense
32.61M99.69%
Net income
-48.24M-58.21%
Net profit margin
-6.87K93.69%
Earnings per share
-0.20
EBITDA
-46.59M-54.39%
Effective tax rate
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
170.03M22.89%
Total assets
229.43M18.08%
Total liabilities
134.81M74.68%
Total equity
94.62M
Shares outstanding
244.92M
Price to book
5.62
Return on assets
-46.19%
Return on capital
-53.15%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-48.24M-58.21%
Cash from operations
Cash from investing
Cash from financing
Net change in cash
Free cash flow
About
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
Founded
1995
Employees
285
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu